

Women's and Children

Medical Genetics

DNA Nucleotide Excision Repair Disorders Service (all ages)

1648

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
1648-(HSS)19-101a	Proportion of patients with a newly confirmed diagnosis of XP being offered support within 10 working days of referral	The number of XP patients who are offered support within 10 working days of referral	Number of patients with a newly confirmed diagnosis of XP during reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648(HSS)-19-102	Proportion of XP patients with UV filter films fitted to home, work, school and car windows	Number of XP patients with UV filter films fitted to home, work, school and car windows	Number of XP patients on caseload	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648(HSS)-19-103	Proportion of XP patients using visors, gloves, hats, eye cover when outside	Number of XP patients using visors, gloves, hats, eye cover when outside	Number of XP patients on caseload	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648-(HSS)19-104a	Proportion of patients living in a UV-safe home environment as defined by a safe reading on the UV meter	Number of patients who are found to be living in a UV safe home environment	Total number of patients whose home environment was assessed during the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648(HSS)-19-105	Mean annual number of sunburn episodes reported for XP patients	Mean annual number of sunburn episodes reported for XP patients		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
1648(HSS)-19-106	Proportion of skin cancers with complete staging information for XP patients	Number of skin cancers with complete staging information for XP patients	Number of XP patients on caseload	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648(HSS)-19-107	Proportion of eye cancers with complete staging for XP patients	Number of eye cancers with complete staging for XP patients	Number of XP patients on caseload	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648(HSS)-19-108	Proportion of skin cancers with stage 1 cancer for XP patients	Number of skin cancers with stage 1 cancer for XP patients	Number of XP patients on caseload	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648(HSS)-19-109	Proportion of skin cancers with stage 2 cancer for XP patients	Number of skin cancers with stage 2 cancer for XP patients	Number of XP patients on caseload	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648(HSS)-19-110	Proportion of skin cancers with stage 3 cancer for XP patients	Number of skin cancers with stage 3 cancer for XP patients	Number of XP patients on caseload	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648(HSS)-19-111	Proportion of eye cancers with stage 1 cancer for XP patients	Number of eye cancers with stage 1 cancer for XP patients	Number of XP patients on caseload	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648(HSS)-19-112	Proportion of eye cancers with stage 2 cancer for XP patients	Number of eye cancers with stage 2 cancer for XP patients	Number of XP patients on caseload	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648(HSS)-19-113	Proportion of XP patients with stage 3 eye cancer	Number of XP patients with stage 3 eye cancer	Number of XP patients on caseload	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648(HSS)-19-114	Proportion of patient caseload involved in a clinical trial	Number of XP patients on caseload involved in a clinical trial	Number of XP patients on caseload	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648-(HSS)19-115	Proportion of CS/TTD patients who have Vit D levels measured	Number of patients who have Vitamin D levels measured	Number of XP patients on caseload	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
1648-(HSS)19-116	Proportion of CS/TTD patients with confirmed diagnosis referred to service to be offered support including home-visiting and a bespoke care passport	Number of patients eligible offered home-visiting and a bespoke care passport	Number of patients with confirmed diagnosis of CS/TTD during reporting period.	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23